Oxford Biomedica plc (OXB) Ordinary 50p

Sell:343.00pBuy:343.50p30.00p (8.00%)

FTSE techMARK 100:0.68%
Market closed | Prices delayed by at least 15 minutes
Sell:343.00p
Buy:343.50p
Change:30.00p (8.00%)
Market closed | Prices delayed by at least 15 minutes
Sell:343.00p
Buy:343.50p
Change:30.00p (8.00%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.

Key people

Frank Mathias
Chief Executive Officer, Executive Director
Lucinda Crabtree
Chief Financial Officer, Executive Director
Thierry Cournez
Chief Operating Officer, UK Site Head
Lisa James
Chief People Officer
James Miskin
Chief Quality and Technical Officer
Matthew Treagus
Chief Information Officer
Natalie Walter
Group General Counsel, Company Secretary
Kyriacos Mitrophanous
Chief Innovation Officer
Sebastien Ribault
Chief Commercial Officer
Roch Frederic Doliveux
Independent Non-Executive Chairman of the Board
Stuart Henderson
Non-Executive Vice Chairman of the Board
Colin Bond
Non-Executive Director
Laurence Espinasse
Non-Executive Director
Robert Ghenchev
Non-Executive Director
Click to see more

Key facts

  • EPIC
    OXB
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    GB00BDFBVT43
  • Market cap
    £365.61m
  • Employees
    834
  • Shares in issue
    105.97m
  • Exchange
    London Stock Exchange (LON)
  • Index
    FTSE All Share Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.